ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ACAD 20.55 +0.41 (2.04%)
price chart
Acadia Pharmaceuticals: 4 Different Insiders Have Sold Shares This Month
For example, a CEO of a company could call a broker on January 1 and enter into a plan to sell a particular quantity of shares of his company's stock on March 1, find out terrible news about his company on February 1 that will not become public until ...
News Recap- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Digital Realty ...
Las Vegas, NV - April 24, 2014 - (Tech Sonian) - A biopharmaceutical company ACADIA Pharmaceuticals Inc. (ACAD) focuses on modern treatments that address unmet medical requirements in neurological and connected central nervous system diseases ...
Related articles »  
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare ...
SAN DIEGO, Apr 01, 2014 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological ...
ACADIA Pharmaceuticals Inc. (ACAD) Soars on Unusual Volume with, NPS ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical firm aimed towards on the development and commercialization of innovative medicines that address unmet medical requirements in neurological and associated central nervous system ...
Investors Alert: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Keryx ...  Market News Call
ACADIA Pharmaceuticals Given Consensus Rating of "Buy" by Analysts ...  Mideast Time
Related articles »  
Healthcare Recent Insider Selling: Boston Scientific Corporation (NYSE:BSX ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares advanced 0.83% in last trading session and ended the day on $19.44. ACAD return on equity ratio is recorded as -24.30% and its return on assets is -21.70%.
Related articles »  
Stocks under Consideration: ACADIA Pharmaceuticals (ACAD), Atlas Resource ...
Las Vegas, NV - April 22, 2014 - (TechSonian) - ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological ...
Related articles »  
Watch List: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Geron Corporation ...
Lakeway, NY - (MARKET NEWS CALL) - 4/15/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Small Cap Unusual Volume: ACADIA Pharmaceuticals (NASDAQ:ACAD ...
Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) informed the Company that he would be retiring due to health and family-related considerations. On April 9 ...
Related articles »  
Investor's Alert- ACADIA Pharmaceuticals Inc. (ACAD), Cypress Semiconductor ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) increased 2.47% and closed at $19.92 in the last trading session with the overall traded volume of 2.13 million shares, versus the average volume of 2.49 million shares.
Stocks In Focus: Exelixis, Inc.(NASDAQ:EXEL), Rexahn Pharmaceuticals, Inc ...  Market News Call
Related articles »  
ACADIA Pharmaceuticals CEO Sells $443750 in Stock (ACAD)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.